Does Tigecycline Work Against Resistant Bacteria?
Tigecycline, a glycylcycline antibiotic, targets multidrug-resistant (MDR) bacteria by inhibiting protein synthesis, binding to the 30S ribosomal subunit with higher affinity than older tetracyclines. It shows activity against gram-positive pathogens like methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and gram-negative bacteria including extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and Acinetobacter baumannii.[1][2]
Clinical trials and FDA approval in 2005 highlight its role in complicated skin/skin structure infections (cSSSI) and intra-abdominal infections (cIAI) caused by resistant strains, such as MDR Acinetobacter and Klebsiella with carbapenemases.[3] In vitro data confirm MIC90 values ≤2 μg/mL for many MDR isolates, outperforming tetracyclines against efflux-pump mediated resistance.[4]
Which Specific Resistant Bugs Does It Hit?
Tigecycline covers:
- MRSA and VRE in skin infections.
- MDR Pseudomonas aeruginosa (variable, often higher MICs).
- Carbapenem-resistant Enterobacteriaceae (CRE) like KPC-producing Klebsiella.
- MDR Acinetobacter baumannii, where it remains a last-resort option per IDSA guidelines.[5]
Surveillance studies like TEST (2004–2014) report >90% susceptibility for Enterobacteriaceae and staphylococci globally, though rates dipped slightly for some Acinetobacter strains.[6]
What Limits Its Effectiveness?
Resistance emerges via ribosomal mutations (e.g., 26S rRNA changes) or efflux pumps, but remains low (<5% in most surveillance). Key weaknesses:
- Poor activity against Pseudomonas aeruginosa and Proteus spp. due to intrinsic resistance.
- Limited blood/tissue penetration requires higher doses for bacteremia.
- FDA warning (2010, 2013) on increased mortality risk in ventilated pneumonia vs. comparators, restricting non-approved uses.[7]
Mortality meta-analyses show no overall excess risk in approved indications, but avoid monotherapy for severe infections.[8]
How Does It Stack Up Against Other Antibiotics?
| Pathogen | Tigecycline | Colistin | Meropenem | Vancomycin |
|----------|-------------|----------|-----------|------------|
| MRSA | Strong | Weak | Weak | Strong |
| CRE | Moderate | Strong | Weak | N/A |
| MDR Acinetobacter | Strong | Strong | Weak | N/A |
| VRE | Strong | N/A | N/A | Weak |
Tigecycline bypasses many beta-lactamase and efflux mechanisms where carbapenems fail, but colistin edges it for highly resistant gram-negatives. Combination therapy (e.g., with colistin) boosts outcomes in CRE.[9]
Real-World Use and Guidelines
IDSA recommends tigecycline for MDR Acinetobacter cIAI/cSSSI (2010 guidelines) and as salvage for CRE (2024 CRE guidance).[5][10] Hospital protocols favor it in polymicrobial abdominal infections with resistance. No generic patents noted on DrugPatentWatch.com; available as generic Tygacil since 2020 expiry.[11]
Sources
[1] FDA Label: Tygacil (tigecycline). https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s021lbl.pdf
[2] Jones et al., *Diagn Microbiol Infect Dis* (2005). https://pubmed.ncbi.nlm.nih.gov/16297503/
[3] Postier et al., *Surg Infect* (2005). https://pubmed.ncbi.nlm.nih.gov/15883857/
[4] Peterson, *Clin Infect Dis* (2008). https://pubmed.ncbi.nlm.nih.gov/18444822/
[5] IDSA Guidelines: MDR Gram-Negative (2010/2024). https://www.idsociety.org/practice-guideline/amr-guidance/
[6] Sader et al., *Int J Antimicrob Agents* (2017). https://pubmed.ncbi.nlm.nih.gov/28259530/
[7] FDA Drug Safety Communication (2013). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-certain-patients-treated-tigecycline-tygacil
[8] Cai et al., *Clin Infect Dis* (2010). https://pubmed.ncbi.nlm.nih.gov/20560720/
[9] Tumbarello et al., *Clin Infect Dis* (2012). https://pubmed.ncbi.nlm.nih.gov/22972854/
[10] IDSA CRE Guidance (2024). https://www.idsociety.org/practice-guideline/amr-guidance-2-0/
[11] DrugPatentWatch: Tigecycline. https://www.drugpatentwatch.com/p/tradename/TYGACIL